ReviewExperimental diabetes research2010
Therapeutics of diabetes mellitus: focus on insulin analogues and insulin pumps.
Review in Experimental diabetes research, 2010. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 16 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
16 citing papers in PubMed, 1 synthesis or guideline pooled it.
- Intensive glucose control versus conventional glucose control for type 1 diabetes mellitus.The Cochrane database of systematic reviews · 2014Pooled it
- Fenugreek derived diosgenin as an emerging source for diabetic therapy.Frontiers in nutrition · 2024Review
- Article
- Hormonal regulation of metabolism-recent lessons learned from insulin and estrogen.Clinical science (London, England : 1979) · 2023Review
- Microneedle-Mediated Transdermal Delivery of Biopharmaceuticals.Pharmaceutics · 2023Review
- Injectable Biodegradable Silica Depot: Two Months of Sustained Release of the Blood Glucose Lowering Peptide, Pramlintide.Pharmaceutics · 2022Article
- Combination Therapy with GABA and MgSOInternational journal of endocrinology · 2022Article
- Assessment of the "Second Day" Exercise Effect on Glycemic Control, Insulin Requirements, and CHO Intake in Type 1 Diabetes Adults.Journal of diabetes science and technology · 2021Article
- Insulin Detemir Versus Insulin Glargine in the Hospital: Do Hypoglycemia Rates Differ?Clinical diabetes : a publication of the American Diabetes Association · 2019Article
- Rapid Characterization of Insulin Modifications and Sequence Variations by Proteinase K Digestion and UHPLC-ESI-MS.Journal of the American Society for Mass Spectrometry · 2018Article
- Revisiting amino acids and peptides as anti-glycation agents.MedChemComm · 2018Review
- Weight Management in Patients with Type 1 Diabetes and Obesity.Current diabetes reports · 2017Review
- Two Cases of Allergy to Insulin in Gestational Diabetes.Endocrinology and metabolism (Seoul, Korea) · 2015Article
- Controlling the aggregation and rate of release in order to improve insulin formulation: molecular dynamics study of full-length insulin amyloid oligomer models.Journal of molecular modeling · 2012Article
- Adsorption and desorption of bioactive proteins on hydroxyapatite for protein delivery systems.Journal of drug delivery · 2012Article
- Stabilized glucagon formulation for bihormonal pump use.Journal of diabetes science and technology · 2010Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
1 author.
Funding
No grant is acknowledged in the PubMed record.
Abstract
aimInadequately controlled diabetes accounts for chronic complications and increases mortality. Its therapeutic management aims in normal HbA1C, prandial and postprandial glucose levels. This review discusses diabetes management focusing on the latest insulin analogues, alternative insulin delivery systems and the artificial pancreas.
resultsIntensive insulin therapy with multiple daily injections (MDI) allows better imitation of the physiological rhythm of insulin secretion. Longer-acting, basal insulin analogues provide concomitant improvements in safety, efficacy and variability of glycaemic control, followed by low risks of hypoglycaemia. Continuous subcutaneous insulin infusion (CSII) provides long-term glycaemic control especially in type 1 diabetic patients, while reducing hypoglycaemic episodes and glycaemic variability. Continuous subcutaneous glucose monitoring (CGM) systems provide information on postprandial glucose excursions and nocturnal hypo- and/or hyperglycemias. This information enhances treatment options, provides a useful tool for self-monitoring and allows safer achievement of treatment targets. In the absence of a cure-like pancreas or islets transplants, artificial "closed-loop" systems mimicking the pancreatic activity have been also developed.
conclusionsIndividualized treatment plans for insulin initiation and administration mode are critical in achieving target glycaemic levels. Progress in these fields is expected to facilitate and improve the quality of life of diabetic patients.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.